|

68Ga-XMFH01 PET/Fluorescence Imaging in Prostate Cancer

RECRUITINGN/ASponsored by The First Affiliated Hospital of Xiamen University
Actively Recruiting
PhaseN/A
SponsorThe First Affiliated Hospital of Xiamen University
Started2026-10-21
Est. completion2027-09-30
Eligibility
Age18 Years+
SexMALE
Healthy vol.Accepted

Summary

This study aims to evaluate the feasibility, safety, and diagnostic performance of 68Ga-XMFH01, a novel ACP3-targeted dual-modality PET and fluorescence imaging probe, for preoperative PET/CT imaging and intraoperative fluorescence-guided surgery in patients with prostate cancer.

Eligibility

Age: 18 Years+Sex: MALEHealthy volunteers accepted
Inclusion Criteria:

* Patients diagnosed with prostate cancer who are scheduled to undergo surgical treatment;
* Adult patients (aged 18 years or older);
* No evidence of distant metastases (M0), including nonregional lymph node metastases, bone metastases, or visceral metastases, as determined by conventional imaging (bone scintigraphy, CT, or MRI) or PET/CT;
* Patients with regional pelvic lymph node metastases (N1) are eligible for inclusion;
* Patients who have been fully informed of their disease status, treatment options, and study procedures, and who voluntarily provide written informed consent;
* Patients who are willing and able to comply with the study protocol, including scheduled visits, treatment procedures, and required laboratory and imaging examinations.

Exclusion Criteria:

* Patients who are unwilling or unable to provide written informed consent or cooperate with study procedures;
* Patients who are unable to tolerate PET/CT examinations;
* Patients who have previously received any of the following treatments for prostate cancer: (a) Systemic therapy: More than 2 months of androgen deprivation therapy (ADT) or conventional hormonal therapy, or any prior treatment with novel hormonal agents, chemotherapy, immunotherapy, or targeted therapy. (b) Local therapy: Prior pelvic radiotherapy or surgery for prostate cancer;
* Patients who are medically unfit for or unable to tolerate the planned surgical procedure for prostate cancer.

Conditions4

ACP3CancerPET-CTProstate Cancer (Diagnosis)

Browse More Trials

Trial data from ClinicalTrials.gov. Trial status and eligibility can change — verify directly with the study contact or on ClinicalTrials.gov.

This site does not provide medical advice. Always consult your doctor before considering enrollment in a clinical trial. Learn more on our About page.